Gabelli Funds’s CytomX Therapeutics CTMX Stock Holding History

Gabelli Funds’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,000	Closed	-$155K	–	1303
2026 Q1	$155K	Buy	+33,000	New	+$168K	﹤0.01%	1167

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Gabelli Funds's CTMX Position: Q2 2026 in Review

Gabelli Funds sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 33,000 shares — an estimated $155K sold.

Gabelli Funds first reported a position in CTMX in Q1 2026 and held it in 1 quarter. The position peaked at $155K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Gabelli Funds reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Gabelli Funds sold 33,000 CytomX Therapeutics shares in Q2 2026, an estimated $155K.
Gabelli Funds first reported a position in CytomX Therapeutics in Q1 2026 and held it in 1 quarter.
Gabelli Funds's CytomX Therapeutics position peaked at $155K in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.